通过发色底物法凝血酶原测定控制口服抗凝治疗
Control of oral anticoagulant treatment by chromogenic prothrombin assay.
作者信息
O'Donnell J R, Walker I D, Davidson J F
出版信息
J Clin Pathol. 1987 May;40(5):500-4. doi: 10.1136/jcp.40.5.500.
Abstract
Doses of oral anticoagulants in 50 patients on long term treatment were easily and satisfactorily monitored over six months by an automated chromogenic assay of prothrombin (CPA). It is suggested that chromogenic assay of one or more of the vitamin K dependent coagulation factors would provide a readily standardised alternative to those conventional tests which depend on human brain derived reagents, now regarded as a biohazard.
摘要
通过凝血酶原的自动显色测定法（CPA），对50名接受长期治疗的患者口服抗凝剂剂量进行了为期6个月的监测，操作简便且结果令人满意。有人认为，对一种或多种维生素K依赖凝血因子进行显色测定，将为那些依赖人脑衍生试剂的传统检测方法提供一种易于标准化的替代方法，而人脑衍生试剂现在被视为一种生物危害。
相似文献
1
Control of oral anticoagulant treatment by chromogenic prothrombin assay.通过发色底物法凝血酶原测定控制口服抗凝治疗
J Clin Pathol. 1987 May;40(5):500-4. doi: 10.1136/jcp.40.5.500.
2
Oral anticoagulant control with a chromogenic substrate: calibration, precision and cost.用发色底物进行口服抗凝剂控制：校准、精密度和成本
Clin Lab Haematol. 1982;4(1):27-39. doi: 10.1111/j.1365-2257.1982.tb00056.x.
3
A chromogenic assay of prothrombin compared with coagulation tests during anticoagulant therapy and liver disease.抗凝治疗和肝病期间凝血酶原的显色测定与凝血试验的比较。
Ric Clin Lab. 1981 Jul-Sep;11(3):215-22. doi: 10.1007/BF02890527.
4
5
Control of anticoagulant therapy with a chromogenic substrate.用显色底物控制抗凝治疗。
Haemostasis. 1979;8(1):1-7. doi: 10.1159/000214285.
6
Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.
Blood Coagul Fibrinolysis. 1997 Jan;8(1):48-53. doi: 10.1097/00001721-199701000-00008.
7
Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X.通过因子X的自动显色底物测定法进行口服抗凝治疗的维持控制。
Clin Lab Haematol. 1982;4(2):179-86.
8
Native prothrombin as an alternative to prothrombin time determination for monitoring oral anticoagulant therapy.
Clin Chem Lab Med. 2009;47(2):242-3. doi: 10.1515/CCLM.2009.046.
9
Oral anticoagulant prophylaxis and epidural catheter removal.口服抗凝剂预防与硬膜外导管拔除
Reg Anesth. 1996 Nov-Dec;21(6):517-24.
本文引用的文献
1
Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A.甲型血友病患者凝血酶原、因子 VII 和因子 IX 的周转率。
Scand J Clin Lab Invest. 1961;13:668-72. doi: 10.3109/00365516109137342.
2
Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X.通过X因子显色底物测定法进行口服抗凝治疗的维持控制。
J Clin Pathol. 1980 May;33(5):445-8. doi: 10.1136/jcp.33.5.445.
3
Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.生色肽底物在正常血浆及口服抗凝剂治疗患者血浆中凝血因子II、VII、IX和X测定中的应用。
Haemostasis. 1982;12(3):241-55. doi: 10.1159/000214679.
4
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods.凝血检测中新型合成肽底物：自动化方法的一些实际考量
Semin Thromb Hemost. 1983 Oct;9(4):250-62.
5
Evaluation of an automated prothrombin assay using a chromogenic substrate.使用显色底物对凝血酶原自动检测法进行评估。
Haemostasis. 1984;14(4):307-11. doi: 10.1159/000215080.
6
Standardisation of oral anticoagulant treatment.口服抗凝治疗的标准化
Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1000-1. doi: 10.1136/bmj.287.6398.1000.
7
Determination of plasma prothrombin with a reaction rate analyzer using a synthetic substrate.使用合成底物通过反应速率分析仪测定血浆凝血酶原。
Thromb Res. 1974 Jun;4(6):719-29. doi: 10.1016/0049-3848(74)90016-4.
8
Questions and answers on prothrombin time standardisation in oral anticoagulant control.口服抗凝治疗中凝血酶原时间标准化的问答
Thromb Haemost. 1985 Aug 30;54(2):515-7.
9
Therapeutic ranges in anticoagulant administration.抗凝治疗的治疗范围。
Br Med J (Clin Res Ed). 1985 Jun 8;290(6483):1683-6. doi: 10.1136/bmj.290.6483.1683.
10
Creutzfeldt-Jakob disease pathogen in growth hormone preparations is eliminatable.生长激素制剂中的克雅氏病病原体是可消除的。
Lancet. 1985 Dec 7;2(8467):1299-300. doi: 10.1016/s0140-6736(85)91576-4.
Zotero 插件